Products Infliximab is commercially available as a powder for a concentrate for the preparation of an infusion solution (Remicade, biosimilars: Remsima, Inflectra). It has been approved in many countries since 1999. Biosimilars were released in 2015. Structure and properties Infliximab is a chimeric human murine IgG1κ monoclonal antibody with a molecular mass of 149.1 kDa … Infliximab: Drug Effects, Side Effects, Dosage and Uses
Products Golimumab is commercially available as a solution for injection (Simponi). It was approved in many countries in 2010. Structure and properties Golimumab (Mr = 150 kDa) is a human IgG1κ-monoclonal antibody. Effects Golimumab (ATC L04AB06) has selective immunosuppressive and anti-inflammatory properties. The effects are based on binding to the soluble and membrane-bound proinflammatory cytokine … Golimumab
Products Etanercept is commercially available as a solution for injection (Enbrel, biosimilars). It has been approved in many countries since 2000. The biosimilars Benepali and Erlezi were approved in many countries in 2018. Structure and properties Etanercept is a dimeric fusion protein composed of the extracellular ligand-binding domain of TNF receptor-2 and the Fc domain … Etanercept
Products Certolizumab is commercially available as a solution for injection (Cimzia). It has been approved in many countries since 2007. Structure and properties Certolizumab is the Fab’ fragment of a recombinant humanized antibody. It is conjugated to polyethylene glycol (PEG) and is therefore also known as certolizumab pegol. Effects Certolizumab (ATC L04AB05) has selective immunosuppressive … Certolizumab
